Table 1. Baseline Patient and Eye Characteristics by As-Treated Treatment Group.
Eyes with uveitis treated with [fluocinolone acetonide) Implant or Systemic Therapy in the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study
| Implant | Systemic | P-value* | |
|---|---|---|---|
| Patient characteristics | |||
| No. patients - n | 117 | 115 | |
| Male – n (%) | 36 (30.8%) | 23 (20.0%) | 0.07 |
| Race / Ethnicity | 0.27 | ||
| White, non-Hispanic - n (%) | 68 (58.1%) | 65 (56.5%) | |
| Hispanic - n (%) | 16 (13.7%) | 11 (9.6%) | |
| Black, non-Hispanic - n (%) | 30 (25.6%) | 30 (26.1%) | |
| Other - n (%) | 3 (2.6%) | 9 (7.8%) | |
| Age (yrs) - mean(SD) | 45 (14) | 46 (15) | 0.53 |
| Body mass index (kg/m2) - mean(SD) | 31 (8) | 31 (9) | 0.87 |
| Uveitis characteristics | |||
| Uveitis Stratum (Intermediate vs. Posterior or Panuveitis) - n (%) | 47 (40.2%) | 45 (39.1%) | 0.89 |
| Bilateral Uveitis - n (%) | 79 (67.5%) | 94 (81.7%) | 0.02 |
| Quality of Life measures | |||
| SF-36 Physical Component Score - mean(SD) | 47 (10) | 48 (10) | 0.25 |
| SF-36 Mental Component Score - mean (SD) | 48 (13) | 48 (11) | 0.77 |
| VFQ-25 Composite - mean(SD) | 59 (22) | 63 (20) | 0.17 |
| EQ-5D - mean(SD) | 0.81 (0.18) | 0.83 (0.15) | 0.45 |
| Eye characteristics | |||
| No. eyes - n | 196 | 209 | |
| Treatment | |||
| OP medication use | 33 (16.8%) | 26 (12.4%) | 0.34 |
| Glaucoma risk factor characteristics | |||
| Mean deviation (dB) - median[IQR] | −6.0 [−11.0, −3.5] | −4.6 [−8.1, −2.7] | 0.02 |
| Cup-to-disc ratio - median(IQR] | 0.29 [0.20, 0.37] | 0.30 [0.21, 0.38] | 0.53 |
| Missing data for cup-to disc ratio | 61 (31.1%) | 29 (15.8%) | 0.002 |
| Intraocular pressure (mmHg) - median[IQR] | 14 [12, 17] | 14 [12, 17] | 0.81 |
| Other eye characteristics | |||
| Visual acuity (standardized letters) -median[IQR] | 67 [46, 78] | 72 [57, 81] | 0.003 |
| Anterior chamber cells | |||
| Grade 1+ or higher (≥ 6 cells) - n (%) | 101 (51.5%) | 95 (45.4%) | 0.34 |
| Anterior chamber flare | |||
| Grade 1+ or higher (≥ faint) - n (%) | 102 (52.0%) | 94 (45.0%) | 0.27 |
| Anterior vitreous cells | |||
| Grade 1+ or higher (≥ 11 cells) - n (%) | 149 (81.0%) | 168 (83.6%) | 0.59 |
| Vitreous haze | |||
| Grade 1+ or higher- n (%) | 119 (66.5%) | 138 (69.0) | 0.67 |
*
For patient characteristics, p-values are derived from unequal variance t-tests for continuous variables and Fisher’s Exact Test for categorical variables. For eye characteristics, p-values are derived from robust linear regression with bootstrapped standard errors accounting for clustering for continuous variables and logistic regression with robust estimation of standard errors to account for clustering for binary variables.